Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
[en] Excess matrix degradation is one of the hallmarks of cancer and is an important factor in the process of tumor progression. It is implicated in invasion, metastasis, growth, angiogenesis and migration. Many characteristics of matrix metalloproteinases (MMPs) make them attractive therapeutic and diagnostic targets. MMP expression is upregulated at the tumor site, with localization of activity in the tumor or the surrounding stroma, providing a target for medical imaging techniques. Radioiodinated carboxylic and hydroxamic MMP inhibitors 2-(4′-[123I] iodo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid (9) and 2-(4′-[123I] iodo-biphenyl-4-sulfonylamino)-3-methyl-butyramide (11), their unlabelled standards and precursors were synthesized. Radioiodination was conducted by electrophilic aromatic substitution of the tributylstannyl precursors and resulted in radiochemical yields of 70±5% (n=6) and 60±5% (n=4), respectively. In vitro zymography and enzyme assays showed for both hydroxamic acid and carboxylic acid compounds a good inhibition activity and a high selectivity for MMP-2. In vivo biodistribution in NMRI mice showed no long-term accumulation in organs and the possibility to accumulate in the tumor in a later phase of this study.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Oltenfreiter, R.
Staelens, L.
Hillaert, U.
Heremans, A.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Frankenne, F.
Slegers, G.
Language :
English
Title :
Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
C. Bremer, S. Bredow, U. Mahmood, R. Weissleder, and C.H. Tung Optical imaging of matrix metalloproteinase-2 activity in tumours: feasibility study in a mouse model Radiology 221 2001 523 529
M.J. Broadhurst, P.A. Brown, G. Lawton, N. Ballantyne, N. Borkakoti, K.M.K. Bottomley, M.I. Cooper, A.J. Eatherton, I.R. Kilford, P.J. Malsher, J.S. Nixon, E.J. Lewis, B.M. Sutton, and W.H. Hohnson Design and synthesis of the cartilage protective agent (CPA, Ro32-3555) Bioorg. Med. Chem. Lett. 7 1997 2299 2302
M. Cai, K. Onoda, M. Takao, I.Y. Kyoko, H. Shimpo, T. Yoshida, and I. Yada Degradation of Tenascin-C and activity of matrix metalloproteinase-2 are associated with tumour recurrece in early stage non-small cell lung cancer Clin. Cancer Res. 8 2002 1152 1156
S. Curran, and G.I. Murray Matrix metalloproteinases in tumour invasion and metastasis J. Pathol. 189 1999 300 308
A.J.P. Docherty, J. O'Connell, T. Crabbe, S. Angal, and G. Murphy The matrix metalloproteinases and their natural inhibitors-prospects for treating degenerative tissue-diseases Trends Biotech. 10 1992 200 207
J. Fang, Y. Shing, and D. Wiederschain Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumour model Proc. Natl. Acad. Sci. USA 97 2000 3884 3889
X. Fei, Q.H. Zheng, X. Liu, J.Q. Wang, H.B. Sun, B.H. Mock, K.L. Stone, K.D. Miller, G.W. Sledge, and G.D. Hutchins Synthesis of radiolabelled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents Bioorg. Med. Chem. Lett. 13 2003 2217 2222
S. Furumoto, R. Iwata, and T. Ido Design and synthesis of fluorine-18 labelled matrix metalloproteinase inhibitors for cancer imaging J. Label. Compd. Radiopharm. 45 2002 975 986
S. Furumoto, K. Takashima, K. Kubota, T. Ido, R. Iwata, and H. Fukuda Tumour detection using F-18-labelled matrix metalloproteinase-2 inhibitor Nucl. Med. Biol. 30 2003 119 125
S. Hanessian, N. Moitessier, C. Gauchet, and M. Viau N-aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S1, S1', S2 ' pockets J. Med. Chem. 44 2001 3066 3073
S.P. Hawkes, H. Li, and G.T. Taniguchi Zymography and reverse zymography for detecting MMPs and TIMPs I. Clark Methods in Molecular Biology 2001 Humana Press Inc. Totowa, NJ 399 410
R. Kiyama, Y. Tamura, F. Watanabe, H. Tsuzuki, M. Ohtani, and M. Yodo Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors J. Med. Chem. 42 1999 1723 1738
R. Lang, M. Braun, N.E. Sounni, A. Noel, F. Frankenne, J.M. Foidart, W. Bode, and K. Maskos Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features J. Mol. Biol. 336 1 2004 213 225
N.B. Liabakk, I. Talbot, R.A. Smith, K. Wilkinson, and K. Balkwill Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenaes in colorectal cancer Cancer Res. 56 1996 190 196
E. Maquoi, F. Frankenne, E. Baramova, C. Munaut, N.E. Sounni, A. Remacle, A. Noël, G. Murphy, and J.M. Foidart Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumour cell lines J. Biol. Chem. 275 2000 11368 11378
S. Massa, M. Artico, F. Corelli, A. Mai, R. Di Santo, S. Cortes, M.E. Marongiu, A. Pani, and P. La Colla Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A J. Med. Chem. 33 1990 2845 2849
L.M. Matrisian Metalloproteinases and their inhibitors in matrix remodeling Trends Genet. 6 1990 121 125
L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: multifunctional contributors to tumour progression Mol. Med. Today 6 2000 149 156
J.R. Morphy, T.A. Millican, and J.R. Porter Matrix metalloproteinase inhibitors: current status Curr. Med. Chem. 2 1995 743 762
G.J.P. Murphy, G. Murphy, and J.J. Reynolds The origin of matrix metalloproteinases and their family relationships FEBS Lett. 289 1991 4 7
M.G. Natchus, R.G. Bookland, B. De, N.G. Almstead, S. Pikul, M.J. Janusz, S.A. Heitmeyer, E.B. Hookfin, L.C. Hsieh, M.E. Dowty, C.R. Dietsch, V.S. Patel, S.M. Garver, F. Gu, M.E. Pokross, G.E. Mieling, T.R. Baker, D.J. Foltz, S.X. Peng, D.M. Bornes, M.J. Strojnowski, and Y.O. Taiwo Development of new hydroxamic matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines J. Med. Chem. 43 2000 4948 4963
H. Nagase, and J.F. Woessner Matrix metalloproteinases J. Biol. Chem. 274 1999 21491 21494
P.M. O'Brien, D.F. Ortwine, A.G. Pavlovsky, J.A. Picard, D.R. Sliskovic, B.D. Roth, L.L. Dyer, R.D. Johnson, C.F. Man, and H. Hallak Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors J. Med. Chem. 43 2000 156 166
B. Passlick, W. Sienel, R. Seen-Hibler, W. Wöckel, O. Thetter, W. Mutschler, and K. Pantel Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early stage non-small cell lung cancer Clin. Cancer Res. 6 2000 3944 3948
N. Peress, E. Perillo, and S. Zucker Localization of tissue inhibitor of matrix metalloproteinases in alzheimers-disease and normal brain J. Neuropathol. Exp. Neurol. 54 1995 16 22
A. Scozzafava, and C.T. Supuran Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties J. Med. Chem. 43 2000 1858 1865
W.G. Stetler-Stevenson, L.A. Liotta, and D.E. Kleiner Extracellular matrix 6: role of matrix metalloproteinases in tumour invasion and metastasis FASEB J. 7 1993 1434 1441
Y. Tamura, F. Watanabe, T. Nakatani, K. Yasui, M. Fuji, T. Komurasaki, H. Tsuzuki, R. Maekawa, T. Yoshioka, K. Kawada, K. Sugita, and M. Ohtani Higly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives J. Med. Chem. 41 1998 640 649
J.F. Woessner Matrix metalloproteinases and their inhibitors in connective-tissue remodelling FASEB J. 5 1991 2145 2154
S.M. Wojtowicz, R.B. Dickson, and M.J. Hawkins Matrix metalloproteinase inhibitors Invest. New Drugs 15 1997 61 75
